Observes patient satisfaction and safety of atezolizumab in routine care
Studies how people with lung cancer or liver cancer experience atezolizumab given under the skin.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
Key facts
- Where
- Acquaviva Delle Fonti, Bergamo, Fano (PU), Genoa, Lecce, Mestre, Milan, Misterbianco (CT), Modena, Naples, Novara, Palermo, Ravenna, Rome, Sassari, Trento, and Verona, ItalySee the 22 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you 18 years old or older?
- Which best describes your lung cancer?
Source: NCT07284121, who can take part
Where in Italy
- Ente Ecclesiastico Ospedale Generale Regionale F MiulliAcquaviva Delle Fonti, ItalyTaking people
- Cliniche Gavazzeni SpA Humanitas GavazzeniBergamo, ItalyTaking people
- Azienda Sanitaria Territoriale Pesaro Urbino (AST PU) - Ospedale Santa Croce;UOC Oncologia - Stabilimento di FanoFano (PU), ItalyTaking people
- IRCCS AOU San Martino - ISTGenoa, ItalyTaking people
- Presidio Ospedaliero Vito FazziLecce, ItalyTaking people
- Ospedale dell'AngeloMestre, ItalyTaking people
- Asst Santi Paolo E CarloMilan, ItalyTaking people
- Fondazione IRCCS Ospedale Maggiore PoliclinicoMilan, ItalyTaking people
- Ospedale Maggiore PoliclinicoMilan, ItalyTaking people
- Humanitas Istituto Clinico Catanese S.p.AMisterbianco (CT), ItalyTaking people
- A.O. Universitaria Policlinico Di ModenaModena, ItalyTaking people
- AORN Ospedali dei Colli Ospedale MonaldiNaples, ItalyTaking people
- Az. Osp. CardarelliNaples, ItalyTaking people
- A.O.U. Maggiore della CaritàNovara, ItalyTaking people
- A.O.U. Policlinico Paolo GiacconePalermo, ItalyTaking people
- Casa di Cura La MaddalenaPalermo, ItalyTaking people
- Ospedale Provinciale Santa Maria Delle CrociRavenna, ItalyTaking people
- Policlinico Universitario Agostino GemelliRome, ItalyTaking people
- Università Campus Bio-Medico di RomaRome, ItalyTaking people
- Azienda Ospedaliero-Universitaria di SassariSassari, ItalyTaking people
- Ospedale Santa ChiaraTrento, ItalyTaking people
- Azienda Ospedaliera Universitaria Integrata VeronaVerona, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hoffmann-La Roche
- Trial code
- NCT07284121
- Record updated
- 6 November 2026
- Original description
This is a non-interventional, multi-country, multi-centre, multicohort, primary data collection study, designed to assess patients' reported satisfaction with Atezolizumab Subcutenous (SC) treatment and Health-related Quality of Life (HRQoL), as well as the effectiveness and safety of Atezolizumab SC in participants treated for selected approved indications in routine clinical practice.Read full original descriptionShow less
A Non-Interventional, Multicenter, Multicohort Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Subcutaneous Atezolizumab in Participants Treated in Routine Clinical Practice
This is a non-interventional, multi-country, multi-centre, multicohort, primary data collection study, designed to assess patients' reported satisfaction with Atezolizumab Subcutenous (SC) treatment and Health-related Quality of Life (HRQoL), as well as the effectiveness and safety of Atezolizumab SC in participants treated for selected approved indications in routine clinical practice.
Inclusion: Participants must have one of the following confirmed diagnoses for which atezolizumab is approved in the local SmPC:; Early stage NSCLC following complete resection and platinum-based chemotherapy with a high risk of recurrence and PD-L1 expression on ≥ 50% of TC and with no EGFR-mutant or ALK-positive NSCLC; Metastatic stage NSCLC with PD-L1 expression on ≥ 50% TC or ≥ 10% tumor infiltrating immune cells (IC) and with no EGFR-mutant or ALK-positive NSCLC not previously treated; Extensive-stage small cell lung cancer (ES-SCLC) not previously treated; Advanced or unresectable HCC not previously treated with systemic therapy; Should not have received > 4 prior cycles of IV Atezolizumab.
Exclusion: Not receiving treatment with Atezolizumab according to standard of care and in line with the current SmPC or local labelling; Receiving concomitant systemic anticancer therapy at the time of initiation of Atezolizumab or an Atezolizumab-containing regimen for treatment of the same disease, as per label; Receiving treatment with Atezolizumab as part of a clinical trial, pre-approval access program, compassionate use program, expanded use program, post-trial access program, or continued access program; Unwilling to complete questionnaires related to treatment satisfaction and treatment-related quality of life.